Sj€ ogren's syndrome is the second most common rheumatic disease in which autoimmune response targets exocrine glands (salivary and lacrimal glands) result in clinical symptoms of dry mouth and dry eye. Inflammation of the lacrimal gland induces tear abnormalities that contribute to the inflammation of the ocular surface, which includes ocular mucosa. Thrombospondin-1 (TSP-1) plays a critical regulatory role in the ocular mucosa and as such TSP-1 -/-mice develop spontaneously chronic ocular surface inflammation associated with Sj€ ogren's syndrome. The autoimmune pathology is also accompanied by a peripheral imbalance in regulatory (T reg ) and inflammatory Th17 effectors. In this study, we demonstrate an in-vitro effect of a CD47-binding TSP-derived peptide in the induction of transforming growth factor (TGF)-b1-secreting forkhead box protein 2 (Foxp3 Consistent with these results, topical administration of CD47-binding TSP peptide, both before and after the onset of the disease, attenuates clinical symptoms of SS-associated dry eye in TSP-1 -/-mice. Augmented expression of Foxp3 detected in the draining lymph nodes of TSP peptide -treated mice compared to those treated with control peptide suggests the ability of TSP peptide to restore peripheral immune imbalance. Thus, our results suggest that TSP-derived peptide attenuates Sj€ ogren's syndrome-associated dry eye and autoimmune inflammation by preventing Th17 development while promoting the induction of T regs . Collectively, our data identify TSP-derived peptide as a novel therapeutic option to treat autoimmune diseases.
Summary
Sj€ ogren's syndrome is the second most common rheumatic disease in which autoimmune response targets exocrine glands (salivary and lacrimal glands) result in clinical symptoms of dry mouth and dry eye. Inflammation of the lacrimal gland induces tear abnormalities that contribute to the inflammation of the ocular surface, which includes ocular mucosa. Thrombospondin-1 (TSP-1) plays a critical regulatory role in the ocular mucosa and as such TSP-1 -/-mice develop spontaneously chronic ocular surface inflammation associated with Sj€ ogren's syndrome. The autoimmune pathology is also accompanied by a peripheral imbalance in regulatory (T reg ) and inflammatory Th17 effectors. In this study, we demonstrate an in-vitro effect of a CD47-binding TSP-derived peptide in the induction of transforming growth factor (TGF)-b1-secreting forkhead box protein 2 (Foxp3
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Introduction
Sj€ ogren's syndrome is a rheumatic disease that afflicts both oral and ocular mucosa, as the salivary and lacrimal glands are targeted by the autoimmune response. The inflammatory damage to the lacrimal gland results in compromised tear quality, which perpetuates the inflammation at the ocular surface. Chronic ocular inflammation associated with autoimmune pathology is a major challenge to treat. Most currently applied treatment options to suppress autoimmune inflammation on a long-term basis, including corticosteroids, are associated with intolerable side effects.
Thus, in addition to a greater risk of visual impairment, chronic ocular inflammation carries a large cost and quality of life burden. Therefore, the availability of better treatment alternatives for chronic ocular inflammation is a pressing need in ophthalmology clinics. Given that an imbalance in regulatory and inflammatory immune response is a major factor underlying most autoimmune diseases, many new therapeutic approaches are designed to restore this balance either by inhibiting or blocking inflammatory effectors and their cytokines or by inducing regulatory effectors.
Thrombospondin-1 is also an important contributor to regulatory mucosal immunity at the ocular mucosa. Similar to other mucosal surfaces, such as intestinal or airway mucosa, transforming growth factor (TGF)-b2 is the predominant isoform detectable in conjunctiva [1, 2] . We have shown that the conjunctival goblet cells have the ability to secrete TGF-b2 and activate it in a thrombospondin-1 (TSP-1)-dependent manner, allowing modulation of neighbouring dendritic cell phenotypes towards an immature or tolerogenic state [2] . Recently we reported that antigenpresenting cells (APCs) exposed to TGF-b2 induce forkhead box P3 (Foxp3)
1 regulatory T cells (T regs ) in a TSP-1-dependent manner [3] . Other studies have reported TSP-1 as a negative regulator of dendritic cell maturation as well as the ability of TSP-1-mediated T cell anergy and T reg homeostasis [4] [5] [6] . Moreover, results of in-vitro experiments have demonstrated that both exogenously provided TSP-1 and CD47-binding TSP-1 peptide inhibit APC-derived T helper type 1 (Th1)-promoting interleukin (IL)-12 secretion [7, 8] . Collectively, these findings support the spontaneous development of chronic ocular surface inflammation associated with Sj€ ogren's syndrome in TSP-1-deficient mice [9] [10] [11] . Our recent identification of a polymorphism in the gene encoding TSP-1 that results in reduced TSP-1 expression and its correlation with the susceptibility to chronic ocular surface inflammation in nhumans further confirm findings from murine studies [12] .
Spontaneously developed ocular mucosal inflammation in TSP-1-deficient mice resembles closely that seen in patients with Sj€ ogren's syndrome. Despite appearing normal at birth, these mice develop a chronic ocular surface inflammation with age, with earliest signs detectable in the conjunctiva by 8 weeks and a fully established ocular mucosa inflammation by 12 weeks of age. The disease is characterized by secretory dysfunction of lacrimal gland and conjunctival goblet cells that lead to a gradual decline in tear quality and disruption of the corneal epithelial barrier. These changes are accompanied with the development of a chronic conjunctival inflammation characterized by the presence of inflammatory infiltrates, elevated levels of inflammatory cytokines, loss of mucin secreting goblet cells and reduced tear mucin (MUC5AC) levels [10] .
In this study we demonstrate that a TSP-1-derived peptide (4N1K), in vitro, induces TGFb-secreting Foxp3 1 T regs and inhibits Th17-promoting IL-23 secretion by inflammatory APCs. This effect is also detected in vivo, as TSP-1 peptide inhibits Th17 successfully and promotes Foxp3 1 T reg development. Furthermore, topical administration of 4N1K in TSP-1-deficient mice attenuates clinical symptoms of Sj€ ogren's syndrome-associated ocular surface inflammation while augmenting the expression of T reg marker, Foxp3, in draining lymph nodes. Together our results support therapeutic efficacy of a TSP-1-derived peptide in the treatment of chronic autoimmune inflammation. 
Materials and methods
Mice
Antibodies and reagents
Antibodies were anti-CD3; clone 2C11(BD Biosciences, San Jose, CA, USA), anti-CD47 (Biolegend, San Diego, CA, USA), fluorescence conjugated anti-CD4, anti-CD25 and anti-Foxp3 (BD Biosciences).
Recombinant proteins were mouse IL-2 and mouse interferon (IFN)-g (R&D Systems, Minneapolis, MN, USA). Peptides, TSP peptide 4N1K (KRFYVVMWKK) and control peptide 4NGG (KRFYGGMWKK), were synthesized by Bio Basic (Markham, Ontario, Canada) and reconstituted in sterile phosphate-buffered saline (PBS). Enzyme-linked immunosorbent assay (ELISA) kits were MUC5AC (TSZ ELISA, Waltham, MA, USA), IL-23 and TGF-b1 (eBioscience, San Diego, CA, USA). The T reg isolation kit was purchased from Miltenyi (Bergish Gladbach, Germany). Phorbol myristate acetate (PMA) and ionomycin were purchased from Sigma (St Louis, MO, USA) (PMA) and EMD Millipore (Billerica, MA, USA) (ionomycin). Culture medium RPMI-1640, 10 mM HEPES, 0Á1 mM non-essential amino acid (NEAA), 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin, 200 mM L-glutamine (Lonza, Basel, Switzerland), insulintransferrin-selenium (ITS) 1 1 culture supplement [1 lg/ ml iron-free transferrin, 10 ng/ml linoleic acid, 0Á3 ng/ml Na2Se and 0Á2 lg/ml Fe(NO3)3] were purchased from Sigma.
Serum free medium
Serum-free medium (SFM) was used for in-vitro assays. The medium contained RPMI-1640, 10 mM HEPES, 0Á1 mM NEAA, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin, 200 mM L-glutamine, 0Á1% BSA) and ITS 1 1 culture supplement. In-vitro stimulation of T cells Lymph nodes and spleens were harvested from C57BL/6 mice and a single-cell suspension was prepared by homogenizing them through a 70-lm nylon membrane. The cells were then washed and the red blood cells (RBC) were lysed using RBC lysis buffer [155 mM NH 4 Cl, 10 mM KHCO 3 and 0Á1 mM ethylenediamine teraacetic acid (EDTA)]. Using a T reg cell isolation kit, CD4
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CD25
-T cells were isolated according to the manufacturer's protocol. Purity of isolated cells as determined by flow cytometry was > 97%. Isolated CD4 1 CD25 -T cells (2 3 10 5 per well) were cultured in a 96-well plate and stimulated with plate-bound anti-CD3 (1 lg/ml) antibody together with soluble anti-CD28 (1 lg/ml) in the presence of either control or TSP peptide (10 lM) with or without anti-CD47 (10 lg/ml) antibody. After 48 h of culture, supernatants were collected from peptide-stimulated T cells and tested for levels of total TGF-b1 by ELISA. Activated T cells were isolated, washed and stained for cell surface CD4, CD25 and intracellular Foxp3 using a cell permeabilizing kit (eBioscience). In some experiments activated T cells were stimulated further with anti-CD3 (1 lg/ml) and recombinant mouse (rm)IL-2 (50 U/ml) every 2-3 days for a period of 9 days prior to harvesting. Stained cells were analysed by flow cytometry (BD LSR II; BD Biosciences). Flow cytometric analysis was performed using FlowJo software (Treestar, Inc, Ashland, OR, USA).
In-vitro stimulation of APCs
Macrophages (> 95% F4/801) were harvested from peritoneal fluid of C57BL/6 mice injected with 2 ml of 3% thioglycollate solution (Sigma) 3 days earlier. These APCs (2 3 10 5 per well) were stimulated with IFN-g (500 ng/ml) and lipopolysaccharide (LPS) (10 lg/ml) in SFM for 24 h prior to adding control or TSP peptide (50 lg/ml). Culture supernatants were collected at 18 h to detect IL-23 levels in an ELISA assay and RNA was isolated from stimulated cells to detect expression of p40 in a real-time polymerase chain reaction (PCR).
Real time PCR
Total RNA was isolated from cervical lymph nodes harvested from TSP peptide and control peptide-treated mice, and from APCs using TRIzol Reagent (Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. cDNA was synthesized using the SuperScript VILO cDNA kit (Life Technologies). Real-time PCR was performed on a 7200 Real Time System (Applied Biosystems, Carlsbad, CA, USA) using SYBR Green PCR Master To verify the specificity of the amplification reaction, a melting curve analysis was performed. The fluorescence signal generated at each cycle was analysed using system software. The threshold cycle values were used to determine relative quantification of gene expression with glyceraldehyde-3-phosphate dehydrogenase as a reference gene.
Sj€ ogren's syndrome model -treatment regimen and disease monitoring
A mouse model of Sj€ ogren's syndrome characterized in TSP-1 null mice was used [11] . Mice (total n 5 10 per group)
at the ages of 6 (prior to the onset of ocular surface inflammation) or 12 weeks (after disease onset) were treated topically with control or TSP peptide (10 lg/mouse), bilaterally (5 ml/eye), once a day for 2 weeks. Disease progression was monitored by corneal fluorescein staining and determining tear content of MUC5AC before starting the treatment (baseline) and after 1 and 2 weeks of treatment in the case of 12-week-old mice. In the case of 6-week-old mice disease was monitored at baseline and at 12 weeks of age (with peptide treatment from weeks 6-8). Corneal fluorescein staining was performed as described previously [11] . Briefly, 1% sodium fluorescein (Sigma-Aldrich, St Louis, MO, USA) was applied to the cornea of mice under anaesthesia. Three minutes later, eyes were flushed with PBS to remove excess fluorescein, and corneal staining was evaluated with a slit-lamp microscope using a cobalt blue light. Punctate staining was recorded using a standardized National Eye Institute grading system of 0-3 for each of the five areas of the cornea [13] . Pilocarpine-induced tears were collected as described previously [11] and pooled samples were analysed to determine MUC5AC content in an ELISA. The assay was performed according to the manufacturer's instructions. Detected mucin content was normalized to tear volume, and the result was presented as MUC5AC ng/ml of tear volume.
Statistical analysis
The unpaired Student's t-test was used to determine significant differences between mean values of experimental and control groups. Error bars enclosing mean values in figures represent 6 standard error of the mean (s.e.m.). P < 0Á05 was considered statistically significant.
Results
TSP peptide promotes induction of regulatory immune response
We examined the effect of CD47-binding TSP peptide 4N1K (or control peptide 4NGG) on purified CD4 1 CD25 -T cells activated with anti-CD3/CD28 antibodies for 48 h.
To assess the induction of T regs we analysed Foxp3 expression in activated T cells by flow cytometry and measured levels of TGF-b secreted in culture supernatants. As shown in Fig. 1a , significantly increased numbers of T cells, activated in the presence of TSP peptide, expressed Foxp3 compared with those activated in the presence of the control peptide. Consistently, T cell activation in the presence 
Thrombospondin-derived peptide inhibits APCderived IL-23 and the induction of Th17 effectors
It is known that exogenously provided TSP-1 and CD47-binding TSP-1 peptide both inhibit APC-derived Th1-promoting IL-12 secretion [7, 8] . In this study we assessed the effect of TSP peptide, 4N1K, on Th17-promoting IL-23 secretion by APCs. Thioglycollate-elicited peritoneal macrophages stimulated with IFN-g and LPS were treated with control or TSP peptide. The level of IL-23 secreted in culture supernatants was determined by ELISA. As shown in Fig. 2a , TSP peptide reduced IL-23 secretion by APCs significantly compared with the control peptide. This observation was confirmed by inhibition of the p40 subunit (common to IL-12 and IL 23 cytokines) in TSP peptidetreated APCs as determined by real-time PCR (Fig. 2b) . These results suggest that TSP peptide inhibits the proinflammatory phenotype of APCs by preventing their ability to support inflammatory effectors.
In addition to IL-12 inhibition in APCs, the ligation of CD47 on T cells was reported to inhibit selectively the development of Th1 effectors [14] . Therefore, based on IL-23 inhibition noted in our experiments, we next tested if TSP peptide inhibits induction of Th17 effectors in vivo. To test this possibility we immunized a group of C57BL/6 mice to induce Th17 effectors. We treated these mice (n 5 3 per group) with intraperitoneal injection of either control or TSP peptide on days 1, 3 and 5 postimmunization. On day 7 post-immunization lymph node cells harvested from the peptide-injected mice were stimulated with PMA/ionomycin and analysed by flow cytometry to detect intracellular IL-17 and Foxp3 in CD4 1 cells. As shown in Fig. 3 , reduced numbers of IL-17-expressing CD4 1 T cells were detectable in TSP-peptide-treated mice compared with the control group. This change was also accompanied by an increase in Foxp3-expressing CD4 1 T cells. These results are consistent with our in-vitro results and confirm the ability of TSP peptide to restore the peripheral balance of the regulatory immune response, supporting its potential anti-inflammatory therapeutic effect in autoimmune pathology.
Topically administered TSP-derived peptide limits the disruption of the ocular surface barrier successfully in a mouse model of Sj€ ogren's syndrome
To evaluate the efficacy of TSP-derived peptide, 4N1K, as a therapeutic intervention for autoimmune ocular inflammation, we used a well-established and validated mouse model of Sj€ ogren's syndrome -TSP-1 -/-mice. Although normal at birth, these mice develop chronic ocular surface disease spontaneously by the age of 12 weeks, which increases progressively in severity with age. The onset of the disease is marked by the disrupted corneal barrier integrity detectable by increased fluorescein staining in all 12-week-old TSP-1 -/-mice [11] . Concurrently, the inflammation in the conjunctiva leads to a significant loss of mucin-secreting goblet cells and reduced soluble mucin (MUC5AC) levels in tears [10] . Considering that mice deficient in TSP-1 remain healthy until the age of 6 weeks, we first evaluated the ability of TSP peptide treatment to prevent or attenuate the progression of the spontaneous ocular surface disease. We treated 6-week-old TSP-1-deficient mice, before the onset of ocular surface disease, with topical TSP peptide for 2 weeks, and then evaluated the disease progression at the age of 12 weeks by determining corneal barrier integrity and tear quality. As shown in Fig. 4a ,b, the corneal fluorescein score of untreated and control peptide-treated 12-week-old TSP-1-deficient mice is increased significantly compared with that seen in age-matched wild-type (WT) mice. However, significantly reduced corneal fluorescein staining is detected in 12-week-old TSP-1-deficient mice that received TSP peptide treatment earlier compared with controls. Furthermore, TSP peptide treatment also resulted in preserving tear MUC5AC levels and therefore tear quality. While control peptide-treated mice showed a progressive decrease in tear MUC5AC levels with age, no such decline was detectable in mice treated with TSP peptide (Fig. 4c) . In fact, at the age of 12 weeks, tear MUC5AC level in TSP peptidetreated mice was significantly higher than that detected in mice treated previously with control peptide.
An imbalance in peripheral immune regulation is believed to contribute to autoimmune pathology and, as such, a significant decline in the peripheral Foxp3 1 T reg population was reported in TSP-1-deficient mice [10, 11] . To determine if the therapeutic efficacy of TSP peptide, 4N1K, correlates with restoration of peripheral regulatory response, we harvested draining cervical lymph nodes from TSP-1 -/-mice that were treated with control or TSP peptide. These lymph nodes were harvested at the termination of disease monitoring period. As shown in Fig. 4d , we noted significantly increased levels of message for Foxp3 in mice treated with TSP peptide compared with controls. These results suggest that early TSP peptide treatment prevents successfully the disruption of the corneal barrier associated with Sj€ ogren's syndrome otherwise detectable by the age of 12 weeks in TSP-1-deficient mice.
Therapeutic efficacy of topically administered TSPderived peptide in treating established ocular surface disease in Sj€ ogren's syndrome While TSP peptide, 4N1K, prevented progression of autoimmune ocular diseases successfully, we next evaluated whether this peptide is also effective in resolving an established disease. To assess this, we took advantage of extensively characterized disease stages in the mouse model of Sj€ ogren's syndrome. Treatment with topical eye drops containing either control or TSP peptide was initiated in 12-week-old TSP-1-deficient mice with an established ocular surface disease. Mice were treated daily for a period of 2 weeks. We assessed corneal barrier by fluorescein staining and measured tear MUC5AC levels by ELISA before initiating the treatment (baseline) and after 1 and 2 weeks of treatment. Treatment with TSP peptide led to a significant progressive decline in corneal fluorescein scores compared with those detected in mice treated with control peptide (Fig. 5a) . Such significantly improved corneal barrier integrity from the baseline was detectable within 1 week of TSP peptide treatment, which persisted after completion of the treatment at 2 weeks. Similarly, tear MUC5AC levels also improved significantly in mice treated with TSP peptide for 2 weeks, but not 1 week, compared with those treated with the control peptide (Fig. 5b) . Also, as shown in Fig. 5c , significantly increased expression of Foxp3 was detected in the cervical lymph nodes harvested from TSP peptide-treated mice compared to those treated with control peptide. The recovery of tear MUC5AC levels correlates with restoration of systemic regulation, suggesting inadequate suppression of inflammation achieved by TSP peptide within the first week of treatment. These results demonstrate clearly that the treatment with TSP peptide improves significantly corneal barrier integrity and tear quality, thereby attenuating the ocular surface disease in TSP-1-deficient mice. Overall, these data indicate therapeutic efficacy of TSP peptide in preventing as well as resolving clinical manifestations of autoimmune ocular inflammation.
Discussion
We have reported previously that spontaneous development of Sj€ ogren's syndrome-associated chronic ocular surface inflammation in TSP-1-deficient mice is accompanied with a peripheral imbalance in T reg and pathogenic Th17 effectors [11] . Additionally, the induction of regulatory immune response by APCs exposed to the TGF-b2 in the microenvironment is dependent upon their TSP-1 expression [3] . In this study, using a validated murine model of Sj€ ogren's-associated ocular surface inflammation, we now demonstrate that a peptide derived from the C-terminal domain of TSP-1 (4N1K) is remarkably effective in treating autoimmune ocular surface inflammation. Our results suggest that TSP peptide can target both APCs and T cells to help restore peripheral immune regulation by preventing the development of pathogenic Th17 effectors while promoting the development of Foxp3 1 T regs . Epithelial cells at the ocular surface as well as APCs are known to express TSP-1 [2, 15] , and both these cell types activate their endogenous TGF-b in a TSP-1-dependent manner [2, 9] . This activation requires binding of TSP-1 to its receptor CD36 [16] . Thrombospondin peptide used in this study is derived from the CD47-binding C-terminal domain that is distant from the TGF-b binding portion of the TSP-1 molecule [17] . Therefore, peptide 4N1K does not contain any TGF-b-activating sequence. Indeed, we detected a TGF-b-independent ability of 4N1K peptide to induce TGF-b-secreting Foxp3 1 T regs . We have reported previously that CD36-deficient APCs, although failing to activate latent TGF-b, manage to induce Foxp3 expression in activated T cells, presumably via their TSP-1 expression [3] . However, such activated T cells are not functional, as they do not secrete TGF-b. Thus, TGF-b-independent induction of Foxp3 by CD36-deficient APCs differs from that induced by CD47-binding 4N1K peptide. This difference may be due to the ability of APC-derived TSP-1 as a whole molecule to engage multiple receptors on T cells against CD47-driven induction of Foxp3 by 4N1K. Moreover, T reg induction by TSP peptide 4N1K correlates with its efficacy in limiting and resolving autoimmune ocular pathology in the Sj€ ogren's syndrome mouse model used in this study. Highly proinflammatory Th17 effector T cells have been associated with a number of autoimmune diseases [18] . These cells are also known to induce strong B cell proliferation and antibody production [19] . The cytokine IL-23 is pivotal for stabilizing the pathogenicity of such Th17 cells [20] . To our knowledge, our experiments demonstrate for the first time the ability of TSP peptide, 4N1K, to inhibit such a critical heterodimeric cytokine (p19/p40) derived from APCs. We show that such inhibition is achieved by suppressing expression of the p40 subunit, which is also a component of the Th1-promoting heterodimeric cytokine IL-12 (p35/p40). Our results not only confirm previously reported inhibition of IL-12 by 4N1K [7] , but also extend this inhibitory effect to Th17-promoting IL-23. Reduced frequency of IL-17 expressing CD4
1 cells in mice injected with 4N1K is in line with our in-vitro results. These results suggest that an inhibitory effect of 4N1K on Th17 may enhance further its efficacy of T reg induction. Blockade of IL-17 or IL-23 [21] and the induction of T regs [22] are emerging as independently attractive therapeutic strategies to treat autoimmune diseases. In our study the combinatorial effect of 4N1K clearly supports its observed efficacy in treating autoimmune disease in a mouse model.
For ocular diseases, the topical instillation of drugs is the most common and preferred method of drug administration due to ease of access and patient compliance [23] . Moreover, greater permeability of the conjunctival epithelium in combination with greater tissue surface area for drug contact [24] favoured our choice of the topical application of TSP peptide. Penetration and distribution of topically administered TSP peptide to target immune cells in the conjunctiva are probably some of the reasons for its efficacy in improving ocular surface manifestations of Sj€ ogren's syndrome. In particular, the local antiinflammatory effect of TSP peptide potentially relieves inflammatory cytokine-mediated inhibition of tear MUC5AC secretion by conjunctival goblet cells, thus restoring tear mucin levels in TSP-1-deficient mice. The improved tear quality in TSP-peptide-treated mice can help to restore corneal barrier integrity. While, in this study, we demonstrated functional modulation of APCs and T cells by TSP peptide, other immune cells as potential targets remain to be evaluated.
Overall, our results suggest that a TSP-1-derived peptide, 4N1K, attenuates autoimmune ocular inflammation by changing the peripheral immune response to favour T reg induction. Thus, our study takes advantage of the immunomodulatory function of TSP-1 to develop a least invasive method that achieves inhibition of inflammation while restoring peripheral immune regulation. In conclusion, topically administered TSP peptide, 4N1K, represents an effective approach to treat chronic ocular inflammation associated with autoimmune Sj€ ogren's syndrome. Currently available therapeutic options to treat chronic ocular surface inflammation, as seen in Sj€ ogren's syndrome, involve a broad immunosuppression that is accompanied with several undesirable side effects. However, drugs focused upon selective ligands in order to avoid such side effects are often limited in their ability to treat complex and multi-factorial chronic inflammation associated with autoimmune pathology. A molecule with multiple functionalities has the potential to serve as a highly effective therapeutic. Therefore, a TSP peptide such as 4N1K with multiple targets, as demonstrated in this study, is a promising candidate for development as a therapeutic entity for chronic ocular inflammation. Our results in preclinical mouse models strongly support this possibility.
